Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Other Non Operating Income (2016 - 2025)

Ptc Therapeutics has reported Other Non Operating Income over the past 14 years, most recently at -$12.5 million for Q4 2025.

  • Quarterly results put Other Non Operating Income at -$12.5 million for Q4 2025, down 241.76% from a year ago — trailing twelve months through Dec 2025 was -$18.1 million (down 376.38% YoY), and the annual figure for FY2025 was -$18.1 million, down 376.38%.
  • Other Non Operating Income for Q4 2025 was -$12.5 million at Ptc Therapeutics, down from $6.5 million in the prior quarter.
  • Over the last five years, Other Non Operating Income for PTCT hit a ceiling of $35.1 million in Q4 2022 and a floor of -$38.1 million in Q3 2022.
  • Median Other Non Operating Income over the past 5 years was -$3.9 million (2024), compared with a mean of -$5.4 million.
  • Biggest five-year swings in Other Non Operating Income: tumbled 1183.82% in 2022 and later surged 447.33% in 2025.
  • Ptc Therapeutics' Other Non Operating Income stood at -$31.4 million in 2021, then soared by 212.02% to $35.1 million in 2022, then crashed by 46.05% to $19.0 million in 2023, then plummeted by 53.33% to $8.8 million in 2024, then plummeted by 241.76% to -$12.5 million in 2025.
  • The last three reported values for Other Non Operating Income were -$12.5 million (Q4 2025), $6.5 million (Q3 2025), and -$5.7 million (Q2 2025) per Business Quant data.